10 May 2024
TruSpine Technologies plc
("TruSpine" or the "Company")
Notice of 2023 AGM
TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that notice of the Company's 2023 annual general meeting ("2023 AGM") will be sent to shareholders shortly.
The 2023 AGM will be held at the offices of Hill Dickinson LLP at The Broadgate Tower, 20 Primrose Street, London, EC2A 2EW on 7 June 2024 at 11:30 am.
A copy of the notice of the 2023 AGM, along with the form of proxy, will be shortly available from the Company's website http://truspine.org/
The Directors of the Company are responsible for the release of this announcement.
Enquiries:
TruSpine Technologies Plc |
Tel: +44 (0)20 7118 0852 |
Geoff Miller, Non-executive Chairman |
|
|
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser) |
Tel: +44 (0)20 7213 0880 |
Liam Murray / Ludovico Lazzaretti |
|
Peterhouse Capital Limited (Broker & Financial Adviser) |
|
Lucy Williams / Duncan Vasey
|
|
Novus Communications (PR and IR) |
Tel: +44 (0)207 448 9839 |
Alan Green / Jacqueline Briscoe |
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.